$ADPT News

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Adaptive Biotechnologies Corporation 2026 Q2 - Results - Earnings Call Presentation

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance

UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65.886M Estimate

Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22

BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies Business Separation May Unlock Greater Value

BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M)

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses